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eTable 1. Descriptive summaries by study of baseline characteristics of participants, follow up time, and number of outcomes contributed. 
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mean (SD) 
Follow up (yrs) 






































 Cohort                                       
ATTICA1 1 1442 744 (52%) 50.5 (11.0) 5.0 (5.0, 5.0) 0.13 (1.10) 0 0 0 0 0 0 0 0 25 25 17 0 42 
BRUN2 1 817 398 (49%) 57.9 (11.4) 15.3 (3.9, 15.5) 0.48 (0.94) 54 31 23 19 40 15 24 0 7 56 123 1 180 
BWHHS3 1 3156 0 (0%) 68.5 (5.5) 4.6 (2.0, 5.6) 0.52 (1.14) 55 23 32 12 46 4 20 14 13 54 148 2 204 
CAPS4 1 848 848 (100%) 57.3 (4.6) 8.0 (4.1, 8.3) 0.51 (1.05) 56 19 37 12 2 0 0 2 6 27 60 0 87 
CHS5 1 4333 1658 (38%) 72.3 (5.2) 11.1 (1.9, 12.9) 0.89 (1.02) 640 233 407 233 514 67 406 41 62 297 864 2 1163 
COPEN6 1 7479 3172 (42%) 59.7 (13.5) 7.3 (1.8, 8.8) 0.73 (0.78) 248 32 216 0 301 35 166 85 90 138 520 68 726 
EAS7 1 754 365 (48%) 64.2 (5.6) 15.1 (2.3, 15.7) 0.60 (1.10) 60 28 32 21 50 2 0 44 13 56 155 2 213 
ESTHER8 1 7894 3304 (42%) 61.6 (6.6) 2.0 (1.9, 2.7) 0.74 (1.08) 58 10 48 8 86 1 3 81 4 21 68 11 100 
FINRISK979 1 1266 1266 (100%) 61.6 (8.6) 6.8 (1.8, 6.9) 0.61 (1.19) 72 24 48 14 57 11 46 0 12 39 90 1 130 
FRAMOFF10 1 3296 1498 (45%) 55.3 (9.7) 11.6 (4.2, 14.3) 0.60 (1.46) 121 13 108 0 68 7 60 0 6 19 194 32 245 
GOH11 1 567 277 (49%) 70.6 (6.6) 3.9 (0.3, 6.9) 0.90 (0.96) 0 0 0 0 0 0 0 0 0 0 0 16 16 
GOTOW12 1 36 0 (0%) 48.9 (7.9) 20.4 (0.5, 32.6) 2.41 (0.74) 7 4 3 4 7 0 0 7 3 9 9 0 18 
HELSINAG13 1 391 105 (27%) 79.5 (4.4) 7.9 (1.7, 11.0) 0.56 (1.21) 38 38 0 27 43 2 20 4 22 103 117 15 235 
HISAYAMA14 1 2578 1088 (42%) 59.0 (11.5) 14.2 (3.4, 14.2) -0.68 (1.28) 77 10 67 3 220 49 148 0 59 76 311 2 389 
HOORN15 1 531 254 (48%) 63.9 (7.2) 8.7 (2.7, 9.9) 0.43 (1.24) 19 4 15 3 13 0 2 11 15 22 30 21 73 
KIHD16 1 2040 2040 (100%) 52.5 (5.3) 19.2 (3.0, 23.1) 0.27 (0.96) 394 11 383 6 146 34 106 3 26 46 257 1 304 
LASA17 1 1518 689 (45%) 69.7 (8.4) 9.7 (1.6, 10.4) 0.77 (1.18) 25 0 25 0 14 0 0 14 0 0 0 428 428 
MESA18 1 6716 3170 (47%) 62.2 (10.2) 4.8 (2.5, 5.2) 0.65 (1.16) 83 14 69 0 84 13 68 2 6 21 120 1 142 
MOGERAUG119 1 874 874 (100%) 53.9 (5.8) 12.9 (3.6, 13.4) 0.47 (1.14) 79 32 47 26 5 2 0 2 24 61 65 0 126 
MOGERAUG2 1 1265 1265 (100%) 58.7 (8.4) 7.8 (1.3, 8.4) 0.52 (1.14) 74 34 40 28 3 1 0 1 8 45 66 2 113 
MOGERAUG3 1 3152 1596 (51%) 54.9 (10.4) 3.0 (2.0, 3.6) 0.42 (1.09) 16 5 11 5 4 1 2 1 9 18 27 0 45 
MOSWEGOT20 1 745 362 (49%) 49.0 (9.5) 8.7 (7.6, 9.2) 0.69 (1.23) 8 1 7 1 16 4 8 2 1 5 21 0 26 
NHANESIII21 1 3722 1434 (39%) 55.6 (15.6) 8.2 (3.0, 11.2) 1.99 (0.70) 137 137 0 49 58 0 0 58 67 262 391 2 655 
NPHSII22 1 2637 2637 (100%) 57.2 (3.6) 7.6 (3.1, 9.9) 1.09 (1.18) 166 16 150 13 38 3 23 8 22 41 120 1 162 
NSHS23 1 1448 695 (48%) 53.8 (15.0) 9.7 (2.4, 10.0) 0.52 (1.32) 5 5 0 0 30 0 0 30 0 5 9 0 14 
QUEBEC24 1 1913 1913 (100%) 56.3 (6.9) 5.3 (4.6, 5.6) 0.56 (1.13) 40 5 35 4 9 0 0 9 12 17 45 2 64 
RANCHO25 1 1381 578 (42%) 67.0 (11.1) 14.6 (2.0, 17.8) 0.51 (1.11) 161 1 160 1 131 1 0 127 71 76 274 1 351 
ROTT26 1 4825 1824 (38%) 67.7 (8.2) 12.0 (2.9, 14.2) 0.53 (1.04) 249 35 214 30 146 23 39 64 275 456 796 181 1433 
SHS27 1 3194 1157 (36%) 59.7 (7.9) 8.9 (1.7, 10.3) 1.38 (1.00) 286 90 196 38 133 5 4 120 76 189 503 8 700 
SPEED28 1 1576 1576 (100%) 57.7 (4.4) 13.9 (2.8, 15.3) 0.42 (1.14) 154 90 64 78 56 2 46 5 12 115 194 0 309 
TARFS29 1 2006 979 (49%) 51.6 (11.1) 4.5 (0.9, 8.2) 0.85 (1.23) 39 28 11 8 20 0 1 19 17 60 48 3 111 
ULSAM30 1 1014 1014 (100%) 71.4 (1.7) 12.1 (2.1, 14.9) 0.66 (1.01) 145 47 98 19 111 16 83 7 38 88 199 2 289 
WHITEI 1 3954 3954 (100%) 76.4 (4.6) 8.2 (2.0, 8.4) 0.52 (1.11) 209 209 0 92 137 14 20 71 111 457 743 14 1214 
WHITEII31 1 7496 5201 (69%) 49.5 (6.0) 7.6 (3.8, 8.2) -0.09 (1.18) 161 23 138 18 6 0 1 3 11 40 95 1 136 
WHS32 1 27938 0 (0%) 54.7 (7.1) 10.2 (8.4, 10.8) 0.62 (1.21) 249 10 239 4 284 26 237 2 82 96 544 0 640 
Subtotal 35 114802 47935 (42%) 60.3 (8.6) 8.2 (2.0, 14.2) 0.65 (1.12) 4185 1262 2923 776 2878 338 1533 837 1205 3040 7223 820 11083 
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 Case-cohort                                       
ARIC33 1 1183 687 (58%) 58.6 (5.5) 10.8 (1.8, 12.7) 0.67 (1.11) 249 36 213 21 44 1 39 2 19 57 71 1 129 
FINRISK9234 1 864 459 (53%) 51.8 (9.2) 11.8 (1.8, 11.9) 0.62 (1.15) 97 20 77 8 80 21 56 0 13 36 112 1 149 
Subtotal 2 2047 1146 (56%) 55.2 (7.3) 11.2 (1.8, 12.6) 0.65 (1.13) 346 56 290 29 124 22 95 2 32 93 183 2 278 
 Nested case-control 
(frequency matched) 
                                      
BRHS35 1 1298 1298 (100%) 51.9 (5.3) 20.5 (3.2, 23.6) 0.50 (1.22) 456 189 267 128 68 0 2 62 24 233 178 1 412 
REYK36 1 5457 3880 (71%) 54.4 (8.3) 21.3 (4.1, 36.6) 0.31 (1.12) 2009 751 1258 552 334 64 102 92 212 1297 1503 31 2831 
Subtotal 2 6755 5178 (77%) 53.2 (7.8) 21.2 (3.8, 35.3) 0.40 (1.14) 2465 940 1525 680 402 64 104 154 236 1530 1681 32 3243 
 Nested case-control 
(individually matched) 
                                      
EPICNOR37 1 3316 2105 (63%) 65.3 (7.8) 7.5 (3.4, 9.3) 0.59 (1.18) 481 228 253 4 0 0 0 0 19 247 105 0 352 
FIA38 1 1612 1176 (73%) 54.9 (7.6) 3.5 (0.4, 8.5) 0.44 (1.04) 583 123 460 123 0 0 0 0 0 123 0 0 123 
FLETCHER39 1 620 478 (77%) 56.9 (14.4) 5.5 (2.1, 6.4) 0.20 (1.01) 128 0 0 0 0 0 0 0 0 0 0 0 0 
GLOSTRUP40 1 382 281 (74%) 50.3 (8.5) 4.5 (0.5, 12.5) 0.58 (1.03) 75 17 58 17 0 0 0 0 0 17 0 0 17 
HPFS41 1 730 730 (100%) 63.1 (8.3) 7.7 (3.0, 8.5) 0.28 (1.17) 221 37 184 11 7 3 2 1 34 78 20 0 98 
MRFIT42 1 737 737 (100%) 46.5 (5.6) 7.1 (6.0, 7.8) 0.70 (0.79) 246 148 98 13 0 0 0 0 0 19 5 0 24 
NHS43 1 720 0 (0%) 60.4 (6.5) 8.0 (1.3, 8.8) 0.89 (1.16) 238 30 208 30 0 0 0 0 3 33 11 1 45 
PRIME44 1 916 916 (100%) 55.2 (2.8) 5.2 (1.9, 7.3) 0.40 (1.10) 143 17 126 12 6 2 4 0 14 31 3 0 34 
USPHS45 1 938 938 (100%) 59.6 (9.1) - 0.20 (0.94) 246 22 224 22 154 0 154 0 0 27 0 0 27 
WHIHABPS46 1 1548 0 (0%) 68.5 (6.3) 6.8 (1.2, 9.3) 1.01 (1.13) 49 6 43 0 706 0 706 0 1 12 24 2 38 
Subtotal 10 11519 7361 (64%) 58.1 (7.8) 6.6 (1.4, 9.0) 0.53 (1.09) 2410 628 1654 232 873 5 866 1 71 587 168 3 758 
 Clinical trials                                       
AFTCAPS47 1 5398 4589 (85%) 58.3 (7.2) 5.1 (4.5, 6.7) 0.55 (1.03) 102 3 99 3 17 0 16 1 14 18 23 0 41 
LEADER48 1 434 434 (100%) 67.1 (9.1) 3.8 (0.8, 4.9) 1.51 (0.93) 36 25 11 13 24 0 15 9 7 37 30 3 70 
PROSPER49 1 3179 1320 (42%) 75.1 (3.3) 3.2 (1.1, 3.8) 1.12 (1.12) 261 64 197 0 112 0 0 112 13 86 150 0 236 
USPHS250 1 10724 10724 (100%) 63.7 (7.7) 10.9 (4.9, 11.5) -0.11 (1.06) 311 28 283 2 259 40 217 2 75 105 690 0 795 
WOSCOPS51 1 5451 5451 (100%) 55.1 (5.5) 4.8 (2.9, 6.0) 0.53 (1.07) 335 64 271 0 62 0 0 62 6 70 88 0 158 
Subtotal 5 25186 22518 (89%) 63.9 (6.8) 5.6 (3.0, 11.4) 0.72 (1.06) 1045 184 861 18 474 40 248 186 115 316 981 3 1300 
Total 54 160309 84138 (52%) 59.8 (8.2) 8.0 (2.0, 15.1) 0.62 (1.11) 10451 3070 7253 1735 4751 469 2846 1180 1659 5566 10236 860 16662 
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eTable 2. Study level characteristics and laboratory methods for measurement of CRP. 
 
Study Geographical location Population source/sampling method Fasting status at 
blood 
sampling/duration 










Assay standard Assay source 
AFTCAPS† USA Popln. Screening/Complete Fasted / > 8 hrs Serum < 1 week NS EIA (Behring) Manufacturer Commercial 
ARIC USA Household listings/Random Fasted / > 8 hrs Plasma > 10 yrs Frozen, -70 ITA (Denka Seiken) Manufacturer Commercial 
ATTICA Greece Popln. Register/Random Fasted / >8hrs Serum < 1 week Fresh INA ( Behring) Manufacturer Commercial 
BRHS UK GP lists/Random Non-fasted Serum > 10 yrs Frozen, -20 MEIA (Abbott) WHO 85/506 Commercial 
BRUN† Italy Popln. Register/Random Fasted / > 8 hrs Plasma > 10 yrs Frozen, -70 ITA / INA, Behring IFCC  CRM 470 Commercial 
BWHHS UK Popln. Register/Random Fasted / >8 hrs Serum 1-5 yrs Frozen, -80 INA ( Behring) Manufacturer Commercial 
CAPS UK Electoral rolls/Random Fasted / > 8 hrs Plasma NS Frozen, -70 EIA (Behring) WHO 85/506 Commercial 
CHS† USA Medicare lists/Random  Fasted / > 8 hrs Plasma 5-10 yrs Frozen, -70 ELISA (In-house) WHO 85/506 In-house 
COPEN† Denmark Popln. Register/Random Non-fasted Serum > 10 yrs Frozen, -80 ITA (DAKO) Manufacturer Commercial 
EAS Scotland GP list/Random Fasted/ > 8 hrs Serum > 10 yrs Frozen, -50 INA ( Behring) Manufacturer Commercial 
EPICNOR UK GP lists/Complete Non-fasted Serum NS Frozen, -80 ELISA (Sanquin Res) Behringwerke Commercial 
ESTHER Germany GP list/Complete Fasted/ NS Serum 1 week-1 yr Frozen, -80 ITA (ADIVA) Manufacturer Commercial 
FIA† Sweden Popln. Register/Random Fasted / 4  hrs Plasma 5 – 18 yrs Frozen, -80 CIA (Immulite ) WHO 85/506 Commercial 
FINRISK92 Finland Popln. Register/Random Fasted / 4-8 hrs Serum  > 10 yrs Frozen, -20 CIA (Immulite ) Manufacturer Commercial 
FINRISK97 Finland Popln. Register/Random Fasted / 4-8 hrs Serum  1 week - 1 yr Frozen, -70 ELISA, Eucardio Lab Manufacturer Commercial 
FLETCHER† New Zealand Occup. , electoral roll/Complete, random Non-fasted Plasma > 10 yrs Frozen, -70 INA (Behring) Manufacturer Commercial 
FRAMOFF† USA Offspring & spouse to FHS/Complete Fasted / > 8 hrs Serum 3 - 7 yrs Frozen, -70 ELISA (Hemagen) WHO Commercial 
GLOSTRUP Denmark Popln. Register/Random Fasted / > 8 hrs Serum 7-15 yrs Frozen, -20 ELISA (In-house) Behring In-house 
GOH Israel Popln. Register/Random Fasted / > 8 hrs Plasma < 1 week Fresh Olympus Manufacturer Commercial 
GOTOW‡ Sweden Popln. Register/Random Fasted / > 8 hrs Serum NS NS NS NS NS 
HELSINAG Finland Popln. Register/Random Fasted / > 8 hrs Serum 5-10 yrs Frozen, -20 EIA (Medix Diacor) WHO 85/506 Commercial 
HISAYAMA Japan Popln. Register/Complete Fasted / > 8 hrs Serum > 10 yrs Frozen, -20 INA ( Behring) Manufacturer Commercial 
HOORN Netherlands Popln. Register/Random Fasted / >8 hrs Plasma 5-10 yrs Frozen, -70 ELISA (DAKO) Behring Commercial 
HPFS USA Occupational/Complete 2/3 Fasted / NS Plasma 5-10 yrs Frozen, -130 ITA (Denka Seiken) Denka Seiken Commercial 
KIHD Finland Popln. Register/Random Fasted / > 8 hrs Serum > 10 yrs Frozen, -20 CIA (Immulite ) WHO 85/506 Commercial 
LASA† Netherlands Popln. Register/Random Non-fasted Serum 5 - 10 yrs Frozen, -80 ELISA (In-house) In-house In-house 
LEADER† UK GP listings/Complete Non-fasted Serum NS Frozen, -70 CIA (Immulite ) NS Commercial 
MESA† USA Popln. Register/Random Fasted / > 8 hrs Plasma 1 week - 1 yr Frozen, -70 INA (Behring) CDC Commercial 
MOGERAUG1† Germany Popln. Register/Random Non-fasted Serum  > 10 yrs Frozen, -80 IRMA, In-house WHO 85/506 In-house 
MOGERAUG2 Germany Popln. Register/Random Non-fasted Serum > 10 yrs Frozen, -80 IRMA, In-house WHO 85/506 In-house 
MOGERAUG3 Germany Popln. Register/Random Non-fasted Serum 1-5 yrs Frozen, -80 IRMA, In-house WHO 85/506 In-house 
MOSWEGOT Sweden Popln. Register/Random Fasted / > 8 hrs Serum  NS NS NS NS NS 
MRFIT USA Popln. Screening/Complete Fasted / > 8 hrs Plasma 10 yrs Frozen, -50 ELISA (Calbiochem) WHO 85/506 Commercial 
NHANESIII‡ USA Census list/Cluster Fasted / > 6 hrs Serum 1 week – 1 yr Frozen, -70 INA, Behring Manufacturer Commercial 
NHS USA Occupational/Complete Fasted / Variable Plasma 5-10 yrs Frozen, -130 ITA (Denka Seiken) Denka Seiken Commercial 
NPHSII UK GP list/Complete Non-fasted Serum 7-14 years Frozen, -40 ? (Cordia) NS Commercial 
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Study Geographical location Population source/sampling method Fasting status at 
blood 
sampling/duration 










Assay standard Assay source 
NSHS Canada Medicare lists/Random Fasted / > 8 hrs Plasma > 10 yrs Frozen, -80 INA ( Behring) NS Commercial 
PRIME France / Northern Ireland General Popln./Quota Fasted / > 8 hrs Plasma 5-10 yrs Frozen, -130 INA ( Behring) NS Commercial 
PROSPER Scotland/Ireland/Netherlands Primary Care screening/Complete Fasted / >8 hrs Plasma 1-5  yrs Frozen, -80 ITA (Roche) cFas calibrator Commercial 
QUEBEC Canada Popln. Register/Random Fasted / > 8 hrs Plasma 5-10 yrs Frozen, -70 INA ( Behring) Manufacturer Commercial 
RANCHO USA Household listings/Complete Fasted /  > 8 hrs Plasma > 10 yrs Frozen, -70 INA ( Behring) NS Commercial 
REYK Iceland Popln. Register/Complete Fasted / > 8 hrs Serum NS Frozen, -20 ITA (Roche) WHO 85/506 Commercial 
ROTT† Netherlands Popln. Register/Complete Non-fasted Serum > 10 yrs Frozen, -20 INA (Immage) Manufacturer Commercial 
SHS USA Tribal rolls/Complete Fasted / > 8 hrs Plasma NS Frozen, -80 ELISA (In-house) In-house In-house 
SPEED UK GP list/Complete Fasted / >8hrs Plasma NS Frozen, -20 EIA (Behring) WHO 85/506 Commercial 
TARFS† Turkey Household listings/Random Fasted /  > 8 hrs Plasma < 1 week Frozen, -80 INA ( Behring) Manufacturer Commercial 
ULSAM† Sweden Popln. Register/Complete Fasted/ > 8 hrs Serum >10 yrs Frozen, -150 INA ( Behring) NS Commercial 
USPHS USA Occupational/Complete Non-fasted Plasma > 10 yrs Frozen, -80 ELISA (In-house) WHO 85/506 In-house 
USPHS2 USA Occupational/Complete Fasted / >8hrs Plasma NS NS ELISA (In-house) WHO 85/506 In-house 
WHIHABPS USA Popln. Register/Complete Fastes/NS Plasma 7-12 yrs Frozen, -70 ITA (Denka Seiken) NS Commercial 
WHITEI UK Occupational/Complete Fasted / > 8 hrs Plasma NS Frozen, -150 INA ( Behring) Manufacturer Commercial 
WHITEII UK Civil servant/Complete Fasted /NS Serum NS Frozen, -80 INA (Behring) NS Commercial 
WHS USA Health professionals/Complete 3/4 Fasted / >8 hrs Plasma 5-10 yrs Frozen, -130 ITA (Denka Seiken) NS Commercial 
WOSCOPS UK Heart screening clinic/Complete Fasted /  > 8 hrs Plasma 10 yrs Frozen, -70 ELISA (In-house) IFCC CRM470 In-house 
‡These studies used a non-high sensitivity CRP assay, measuring only CRP values > 2 mg/l 
†These studies have contributed data on baseline and re-survey measurements 
Popln. = Population; Occup./Occupational = Occupation based cohort; GP = General Practitioner; FHS = Framingham Heart Study; NS = Not Stated 
 
  6 
eTable 3. Characterisation of baseline and incident vascular disease outcomes in the contributing studies. 
 
  Coronary heat disease assessed at baseline Definition of incident endpoints Classification of incident endpoints 
    Death Nonfatal MI Nonfatal Stroke MI Stroke 












Definite Probable Silent Ischemic Hemorrhagic SAH Unclassified 
AFTCAPS ++ ++ - - ** ✓ ✓ ✓ ✓ ✓ ✓ - ✓NC ✓NC NS NS ✓NC 
ARIC ++ NC ++ NC ++ NC - ** ✓ ✓ ✓ ✓ ✓ ✓ ✓ NC ✓ NC ✓ ✓ ✓ ✓ 
ATTICA + + + + *  - -  -  -  - - - - - - - - 
BRHS ++ ++ - ++ * ✓ ✓ ✓ NS NS ✓ o o ✓ ✓ ✓ ✓ 
BRUN ++ ++ ++ NC ++ NC ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ o o 
BWHHS ++ ++ ++ - ** ✓ ✓ ✓ ✓  ✓ ✓ o o ✓ ✓ ✓ ✓ 
CAPS ++ ++ NC - - ** ✓ ✓ o ✓ ✓ ✓ ✓ NC o ✓ ✓ ✓ ✓ 
CHS ++ ++ ++ ++ ** ✓ ✓ ✓ ✓ ✓ ✓ ✓ NC ✓ NC ✓ ✓ o ✓ 
COPEN ++ ++ - - ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
EAS ++ ++ - - ** ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ NC ✓ ✓ ✓ ✓ 
EPICNOR + - - - * ✓ ✓ ✓ ✓   ✓ ✓ o o ✓ NC ✓ NC ✓ NC ✓ NC 
ESTHER ++ ++ ++ + ** ✓ ✓ ✓ ✓   ✓ ✓ o o  o  o  o  ✓ 
FIA ++ - - - ** ✓ ✓ ✓ NA NA ✓ o o ✓ NC ✓ NC ✓ NC ✓ NC 
FINRISK92 ++ ++  ++ NC - ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
FINRISK97 ++ ++  ++ NC - ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
FLETCHER + NC + + NC - * ✓ ✓ ✓ ✓ ✓ ✓ o o ✓NC ✓NC ✓NC ✓NC 
FRAMOFF ++ ++ - ++NC ** ✓ ✓ ✓ ✓ ✓ ✓ o ✓ ✓ ✓ ✓ ✓ 
GLOSTRUP ++ ++ ++ NC - ** ✓ ✓ ✓ NA NA ✓ o o o o o ✓ NC 
GOH ++ - - - ** NA NA NA NA NA ✓ ✓ NC o ✓ ✓ ✓ ✓ 
GOTOW ++ NS NS NS * ✓ ✓ ✓ ✓ ✓ ✓ o o NS NS NS ✓ 
HELSINAG ++ NC ++ NC ++ NC ++ NC ** NA NA NA  NA NA ✓ o o ✓ ✓ ✓ ✓ 
HISAYAMA ++ ++ ++ ++ ** ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ ✓ ✓ ✓ ✓ 
HOORN ++ NC ++ NC ++ NC NS * ✓ ✓ ✓ ✓ o ✓  o o ✓  ✓  ✓  ✓  
HPFS + + + - ** ✓ ✓ ✓ NA NA ✓ ✓ NC o o o o o 
KIHD ++ ++ ++ ++ ** ✓ ✓ ✓ ✓ ✓ ✓  ✓ NC o ✓ ✓ ✓ ✓ 
LASA ++ ++ - ++ * NA NA NA ✓ ✓ o O o o o o ✓ 
LEADER ++ ++ - - ** ✓ ✓ ✓ ✓ ✓ ✓ O o ✓ ✓ ✓ ✓ 
MESA + + + + ** ✓ ✓ ✓ ✓ ✓ ✓  NS ✓ ✓ ✓ ✓ ✓ 
MOGERAUG1 + + NC - - ** ✓ ✓ ✓ NA NA ✓ ✓ NC o ✓  ✓ ✓ ✓ 
MOGERAUG2 + + NC - - ** ✓ ✓ ✓ NA NA ✓ ✓ NC o ✓ ✓ ✓ ✓ 
MOGERAUG3 + + NC - - ** ✓ ✓ ✓ NA NA ✓ ✓ NC o ✓ ✓ ✓ ✓ 
MOSWEGOT + + - - ** ✓ ✓ ✓ ✓  ✓ ✓ O o ✓ ✓ ✓ ✓ 
MRFIT ++ ++ - - ** ✓ ✓ ✓ ✓ ✓ ✓ O ✓ ✓ ✓ ✓ ✓ 
NHANESIII + - - + * ✓ ✓ ✓ ✓ ✓ ✓ NC O o ✓ NC ✓ NC ✓ NC ✓ NC 
NHS + + + - ** ✓ ✓ ✓ NA NA ✓ ✓ NC o o o o o 
NPHSII ++ ++ ++ NC +NC ** ✓ ✓ ✓ ✓ ✓ ✓  ✓ NC ✓ NC ✓ ✓ ✓ ✓ 
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  Coronary heat disease assessed at baseline Definition of incident endpoints Classification of incident endpoints 
    Death Nonfatal MI Nonfatal Stroke MI Stroke 












Definite Probable Silent Ischemic Hemorrhagic SAH Unclassified 
NSHS ++ ++ ++ ++ ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
PRIME ++ ++ + - ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
PROSPER ++ ++ ++ ++ ** ✓ ✓ ✓ ✓ ✓ ✓ o o NS NS NS ✓ 
QUEBEC ++ ++ - - ** ✓ ✓ ✓ ✓ ✓ ✓ o ✓ o o o ✓ 
RANCHO ++ ++ ++ + * ✓ ✓ ✓ ✓  ✓ ✓ o o ✓ ✓ ✓ ✓ 
REYK ++ ++ ++ - ** ✓ ✓ ✓ ✓ ✓ ✓ ✓ o ✓  ✓  ✓  ✓  
ROTT ++ ++ NC ++ ++ ** ✓ ✓ ✓ NA NA ✓ ✓ NC o ✓ ✓ ✓ ✓ 
SHS ++ NC ++ NC ++ NC ++ NC ** ✓ ✓ ✓ ✓ ✓ ✓ ✓ NC o ✓ ✓ ✓ ✓ 
SPEED ++ ++NC - - ** ✓ ✓ ✓ ✓ ✓ ✓ o ✓NC ✓ ✓ ✓ ✓ 
TARFS ++ ++ ++ NC - * ✓ ✓ o ✓ o ✓ o ✓ ✓ o o ✓ 
ULSAM ++ ++ ++ ++ ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
USPHS + - - - ** ✓ ✓ ✓ NA NA ✓ o o ✓ NC ✓ NC ✓ NC ✓ NC 
USPHS2 + - - - * ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
WHIHABPS + + + NS ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
WHITEI + + NC + NC + *  - -  -  -  - - - - - - - - 
WHITEII ++ ++ NC ++ NC ++ NC * ✓ ✓ ✓ ✓ ✓ ✓ o o ✓ ✓ ✓ ✓ 
WHS + + + - ** ✓ ✓ ✓ ✓ ✓ ✓ o o ✓  ✓  ✓  ✓  
WOSCOPS ++ ++ ++ NC ++ NC ** ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ NC o o o ✓ 
–: Not recorded; +: Self-report only; ++: Self-report supplemented by objective criteria (e.g., Electrocardiogram, Physical examination) 
* Death certificate only; ** Death certificate supplemented by medical record 
0: Feature not included in criteria; ✓: Feature included in criteria 
SAH: Subarachnoid haemorrhage; NS: Not stated 
NC = reportedly measured but data not contributed to the ERFC; NA = not applicable, where cohorts contributed data on fatal endpoints only 
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eTable 4. Summary of data available and associations with CRP levels.  
 
 Summary of available data Association with loge CRP value 






Percent difference (95% CI) in CRP 
levels per 1 SD increase or 
compared to reference category § 
Loge CRP (mg/l) 54 160309 0.62 (1.11) - 
Age at survey (years) 54 160309 59.8 (8.2) 15% (12%, 17%) 
     
on-lipid markers     
Systolic blood pressure (mmHg) 52 152145 137 (18) 13% (11%, 16%) 
Diastolic blood pressure (mmHg) 52 153810 81 (10) 10% (7%, 12%) 
Body mass index (kg/m2) 53 155391 26.6 (4.4) 37% (33%, 40%) 
     
Lipid markers     
Total cholesterol (mmol/l) 53 157758 5.90 (1.07) 3% (2%, 5%) 
LDL cholesterol (mmol/l) 12 50157 3.51 (0.85) 9% (2%, 16%) 
Non-HDL cholesterol (mmol/l) 51 144752 4.60 (1.07) 10% (8%, 12%) 
HDL cholesterol (mmol/l) 51 144792 1.30 (0.38) -18% (-20%, -16%) 
Loge triglycerides (mmol/l) 46 130201 0.38 (0.51) 21% (17%, 25%) 
     
Inflammatory and metabolic markers     
Fibrinogen level (µmol/l) 32 97146 9.91 (2.27) 72% (64%, 81%) 
Albumin (g/l) 22 61148 43.1 (4.4) -20% (-25%, -15%) 
Loge leukocyte count (x10
9/l) 19 40094 1.85 (0.27) 36% (30%, 42%) 
Loge interleukin 6 (ng/l) 11 26465 0.55 (0.66) 74% (55%, 96%) 
Loge fibrin D-dimer (µg/l) 7 14018 4.57 (0.84) 35% (16%, 57%) 
Fasting glucose (mmol/l) 24 49487 5.83 (1.83) 14% (10%, 18%) 
     
Categorical variables     
Sex     
   Male 49 84138  52% Ref 
   Female 36 76171  48% 8% (1%, 16%) 
Ethnicity     
   White 42 129017  94% Ref 
   Asian 7 3862  3% -16% (-40%, 19%) 
   Black 14 5101  4% 26% (15%, 38%) 
Smoking status      
   Not current 53 125132  79% Ref 
   Current 51 32286  21% 37% (31%, 44%) 
Alcohol consumption     
   Not current 43 49552  35% Ref 
   Current 42 90130  65% -5% (-9%, -1%) 
History of diabetes      
   No 51 143257  94% Ref 
   Yes 48 9650  6% 32% (24%, 41%) 
Physical activity     
   Inactive 27 30331  64% Ref 
   Active 14 16950  36% -24% (-32%, -14%) 
 
§ Percent change in CRP per 1-SD higher value of the row variable (or, for categorical variables, the percentage 
difference in mean CRP levels compared to reference category) adjusted for sex and age, pooled across studies 
using random effects meta-analysis.  
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eTable 5. Risk ratios for vascular disease and non-vascular mortality per 3-fold higher baseline and usual CRP levels and between study heterogeneity statistics. 
 
    Risk ratio (95% CI) per 3-fold higher 
CRP levels† 
 Between study heterogeneity in models 
involving usual loge CRP levels 














Q statistic  
χ
2 (df) 
p-value I2 (95% CI) 
Fatal/ non-fatal CHD and stroke outcomes          
Coronary heart disease 48 151972 10341 1.36 (1.32, 1.40) 1.68 (1.59, 1.78) 317 90 (47) <0.0001 48 (27, 63) 
   Non-fatal MI‡ 25 47113 4610 1.31 (1.24, 1.38) 1.59 (1.45, 1.75) 93 53 (24) 0.001 54 (28, 71) 
   Fatal MI‡ 25 44835 1501 1.43 (1.31, 1.56) 1.84 (1.59, 2.14) 65 39 (24) 0.025 39 (1, 62) 
Ischaemic stroke 23 94761 2611 1.25 (1.18, 1.32) 1.46 (1.32, 1.61) 57 34 (22) 0.049 35 (0, 61) 
Haemorrhagic stroke 13 74548 364 1.04 (0.91, 1.19) 1.07 (0.86, 1.32) 0.3 18 (12) 0.125 32 (0, 65) 
Unclassified stroke 16 54825 953 1.24 (1.13, 1.34) 1.41 (1.22, 1.63) 21 23 (15) 0.084 35 (0, 64) 
Fatal outcomes          
All vascular deaths 37 136912 3430 1.43 (1.35, 1.51) 1.82 (1.66, 2.00) 160 73 (36) <0.0001 51 (28, 66) 
All nonvascular deaths 38 138063 8369 1.29 (1.24, 1.34) 1.55 (1.46, 1.66) 177 86 (37) <0.0001 57 (38, 70) 
Cancer deaths          
   Respiratory / intrathorasic cancer deaths 24 61356 666 1.66 (1.50, 1.83) 2.32 (1.96, 2.74) 95 32 (23) 0.094 29 (0, 57) 
   Breast cancer deaths 8 18276 130 1.46 (1.21, 1.76) 1.88 (1.39, 2.55) 17 6 (7) 0.568 0 (0, 68) 
   Blood related cancer deaths 14 45806 220 1.34 (1.16, 1.54) 1.57 (1.24, 1.99) 14 11 (13) 0.618 0 (0, 55) 
   Digestive cancer deaths 25 64508 906 1.23 (1.12, 1.35) 1.44 (1.23, 1.70) 20 39 (24) 0.028 38 (0, 62) 
   Genitourinary related cancer deaths 17 48646 502 1.26 (1.11, 1.43) 1.45 (1.18, 1.78) 12 23 (16) 0.114 30 (0, 61) 
Non-cancer nonvascular deaths          
   Respiratory disease deaths 22 73342 915 1.35 (1.24, 1.48) 1.67 (1.44, 1.92) 49 29 (21) 0.126 26 (0, 56) 
   Digestive system (except liver) disease deaths 13 32943 173 1.36 (1.13, 1.64) 1.72 (1.24, 2.39) 11 17 (12) 0.138 31 (0, 64) 
   Endocrine, nutritional & metabolic disease deaths 8 24505 180 1.37 (0.99, 1.88) 1.64 (0.97, 2.77) 3.5 18 (7) 0.012 61 (16, 82) 
   Nervous system disorder deaths 11 37397 280 0.92 (0.74, 1.16) 0.90 (0.64, 1.28) 0.3 19 (10) 0.045 46 (0, 73) 
   External causes (violence/suicide/trauma) 19 74631 356 1.14 (1.02, 1.27) 1.26 (1.05, 1.52) 6 12 (18) 0.840 0 (0, 49) 
Unclassified deaths 9 30455 786 1.32 (1.17, 1.49) 1.57 (1.37, 1.81) 41 9 (8) 0.354 10 (0, 68) 
 
† Risk ratios are adjusted only for age, and stratified where appropriate, by sex and trial arm. Studies with fewer than 10 cases of CHD, stroke, and the composite all vascular and all 
non vascular deaths outcomes or 5 cases of the specific nonvascular outcomes were excluded from the analysis of that outcome. The risk ratios are presented per 1.11 higher loge 
CRP (i.e. 1-SD of observed levels at baseline), corresponding to a 3-fold higher CRP levels. 
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eTable 6. Risk ratios for vascular and nonvascular mortality per 3-fold higher usual CRP levels with progressive 
adjustment for usual levels of potential confounders. 
 
 Basic adjustment
¶ Further adjustment¶ 
 RR (95% CI) usual 






I2 (95% CI) RR (95% CI) usual 






I2 (95% CI) 
All vascular deaths 27 studies, 95583 participants, 1810 events 23 studies, 80905 participants, 1544 events 
Adjusted for age, sex, and study 1.77 (1.59, 1.99) 99 41 (6, 63) 1.71 (1.53, 1.91) 86 33 (0, 60) 
plus systolic blood pressure 1.70 (1.52, 1.90) 87 36 (0, 60) 1.64 (1.46, 1.83) 73 30 (0, 58) 
plus smoking 1.62 (1.46, 1.80) 84 22 (0, 52) 1.58 (1.41, 1.77) 61 28 (0, 57) 
plus history of diabetes 1.56 (1.40, 1.73) 67 23 (0, 52) 1.49 (1.33, 1.67) 49 22 (0, 53) 
plus BMI 1.65 (1.47, 1.85) 74 24 (0, 53) 1.59 (1.40, 1.81) 51 30 (0, 58) 
plus loge triglycerides 1.62 (1.45, 1.81) 73 18 (0, 49) 1.55 (1.38, 1.75) 51 21 (0, 53) 
plus total cholesterol 1.65 (1.46, 1.86) 66 30 (0, 56) 1.59 (1.39, 1.81) 45 35 (0, 61) 
plus non-HDL cholesterol§ - - - 1.55 (1.37, 1.76) 49 23 (0, 54) 
plus HDL cholesterol§ - - - 1.56 (1.38, 1.76) 50 23 (0, 54) 
plus alcohol§ - - - 1.55 (1.37, 1.76) 49 23 (0, 54) 
       
8on-vascular deaths 30 studies, 99863 participants, 5109 events 26 studies, 88399 participants, 4599 events 
Adjusted for age, sex, and study 1.54 (1.42, 1.67) 105 56 (34, 71) 1.55 (1.41, 1.69) 93 58 (34, 73) 
plus systolic blood pressure 1.55 (1.43, 1.68) 108 54 (30, 70) 1.56 (1.43, 1.70) 96 56 (32, 72) 
plus smoking 1.47 (1.36, 1.59) 93 45 (15, 64) 1.47 (1.35, 1.60) 82 47 (16, 66) 
plus history of diabetes 1.45 (1.33, 1.57) 76 50 (24, 67) 1.45 (1.33, 1.59) 67 53 (26, 70) 
plus BMI 1.56 (1.42, 1.71) 86 54 (31, 70) 1.57 (1.42, 1.73) 79 55 (30, 71) 
plus loge triglycerides 1.56 (1.43, 1.71) 91 52 (27, 68) 1.57 (1.43, 1.73) 84 52 (25, 70) 
plus total cholesterol 1.54 (1.41, 1.68) 90 50 (24, 67) 1.55 (1.41, 1.71) 83 51 (23, 69) 
plus non-HDL cholesterol§ - - - 1.56 (1.42, 1.72) 85 50 (22, 68) 
plus HDL cholesterol§ - - - 1.55 (1.42, 1.70) 90 46 (15, 66) 
plus alcohol§ - - - 1.54 (1.40, 1.68) 88 45 (12, 65) 
 
† Risk ratios are presented per 1.11 higher loge CRP (i.e. 1-SD of observed levels at baseline), corresponding to a 3-fold 
higher CRP levels, progressively adjusted as shown and stratified where appropriate, by sex and trial arm. 
¶ Analyses were restricted to participants with complete information on sex, trial arm, and all confounding variables. 
Studies with fewer than 10 cases were excluded from the analysis of each outcome.  
§ Non-HDL cholesterol has been substituted for total cholesterol in these adjusted models 
I2 is a measure of consistency across studies: the percentage of variance in estimated log RRs that is attributable to 
between study variation as opposed to sampling variation. Values of I2 close to 0 correspond to lack of heterogeneity. 
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eTable 7. Risk ratios for vascular and non-vascular mortality per 3-fold higher usual CRP levels with 
adjustment for usual levels of conventional risk factors plus inflammatory markers. 
 






RR (95% CI) usual 






I2 (95% CI) 
All vascular deaths       
Adjusted for age, sex, and study 17 64740 1138 1.65 (1.49, 1.83) 89 4 (0, 53) 
plus conventional risk factors 17 64740 1138 1.53 (1.33, 1.75) 36 14 (0, 50) 
plus fibrinogen 17 64740 1138 1.34 (1.18, 1.52) 22 0 (0, 51) 
       
Adjusted for age, sex, and study 9 27005 824 1.67 (1.40, 1.99) 33 49 (0, 76) 
plus conventional risk factors 9 27005 824 1.57 (1.32, 1.87) 26 32 (0, 69) 
plus albumin 9 27005 824 1.46 (1.27, 1.68) 27 13 (0, 55) 
       
Adjusted for age, sex, and study 9 20078 678 1.67 (1.38, 2.01) 29 40 (0, 72) 
plus conventional risk factors 9 20078 678 1.52 (1.30, 1.78) 27 6 (0, 67) 
plus loge leukocyte count 9 20078 678 1.47 (1.24, 1.76) 19 22 (0, 63) 
       
Adjusted for age, sex, and study 5 18054 392 1.48 (1.26, 1.75) 23 0 (0, 79) 
plus conventional risk factors 5 18054 392 1.30 (1.08, 1.56) 8 0 (0, 79) 
plus loge interleukin 6 5 18054 392 1.02 (0.79, 1.32) 0 12 (0, 82) 
       
8on-vascular deaths       
Adjusted for age, sex, and study 18 65311 3472 1.55 (1.39, 1.71) 69 57 (28, 75) 
plus conventional risk factors 18 65311 3472 1.52 (1.37, 1.69) 62 44 (3, 68) 
plus fibrinogen 18 65311 3472 1.34 (1.20, 1.50) 25 49 (12, 70) 
       
Adjusted for age, sex, and study 10 30972 2579 1.64 (1.42, 1.90) 44 75 (53, 87) 
plus conventional risk factors 10 30972 2579 1.53 (1.36, 1.73) 48 51 (0, 76) 
plus albumin 10 30972 2579 1.45 (1.29, 1.62) 41 47 (0, 74) 
       
Adjusted for age, sex, and study 9 20078 1819 1.52 (1.27, 1.83) 21 73 (48, 86) 
plus conventional risk factors 9 20078 1819 1.45 (1.24, 1.70) 22 52 (0, 77) 
plus loge leukocyte count 9 20078 1819 1.36 (1.19, 1.56) 20 43 (0, 74) 
       
Adjusted for age, sex, and study 5 18054 1082 1.51 (1.27, 1.81) 21 66 (12, 87) 
plus conventional risk factors 5 18054 1082 1.49 (1.31, 1.70) 37 50 (0, 82) 
plus loge interleukin 6 5 18054 1082 1.16 (1.03, 1.30) 6 0 (0, 79) 
 
† Risk ratios are presented per 1.11 higher loge CRP (i.e. 1-SD of observed levels at baseline), corresponding to a 3-fold 
higher CRP levels, progressively adjusted as shown and stratified where appropriate, by sex and trial arm. 
¶ The conventional risk factors included age, sex, systolic blood pressure, smoking, history of diabetes, BMI, loge 
triglycerides, non-HDL cholesterol, HDL cholesterol, and alcohol consumption. Analyses were restricted to participants 
with complete information on sex, trial arm, and all the conventional risk factors plus each inflammatory marker in turn. 
Studies with fewer than 10 cases were excluded from the analysis of each outcome.  
I2 is a measure of consistency across studies: the percentage of variance in estimated log RRs that is attributable to 
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eTable 8. Risk ratios for major vascular and nonvascular outcomes per 3-fold higher baseline CRP levels with 
progressive adjustment for baseline levels of potential confounders. 
 Basic adjustment
¶ Further adjustment¶ 
 RR (95% CI) 







I2 (95% CI) RR (95% CI) 







I2 (95% CI) 
Coronary heart disease 37 studies, 109742 participants, 8056 events 31 studies, 91990 participants, 5373 events 
Adjusted for age, sex, and study 1.34 (1.30, 1.39) 258 38 (7, 58) 1.34 (1.28, 1.40) 168 45 (16, 64) 
plus systolic blood pressure 1.32 (1.27, 1.36) 229 35 (3, 56) 1.31 (1.25, 1.37) 148 42 (11, 62) 
plus smoking‡ 1.28 (1.24, 1.32) 214 24 (0, 50) 1.27 (1.22, 1.32) 138 32 (0, 56) 
plus history of diabetes 1.26 (1.22, 1.31) 164 34 (1, 56) 1.25 (1.20, 1.31) 103 41 (10, 62) 
plus BMI 1.25 (1.21, 1.29) 171 21 (0, 47) 1.24 (1.19, 1.29) 105 31 (0, 56) 
plus loge triglycerides 1.23 (1.19, 1.28) 138 25 (0, 50) 1.23 (1.17, 1.28) 86 34 (0, 57) 
plus total cholesterol 1.24 (1.20, 1.28) 150 21 (0, 48) 1.23 (1.18, 1.29) 92 31 (0, 56) 
plus non-HDL cholesterol§ - - - 1.23 (1.18, 1.28) 100 24 (0, 52) 
plus HDL cholesterol§ - - - 1.22 (1.17, 1.27) 92 24 (0, 51) 
plus alcohol§ - - - 1.22 (1.17, 1.27) 84 28 (0, 54) 
       
Ischaemic stroke 17 studies, 65825 participants, 2006 events 15 studies, 60763 participants, 1931 events 
Adjusted for age, sex, and study 1.24 (1.19, 1.31) 77 0 (0, 51) 1.24 (1.18, 1.31) 74 0 (0, 54) 
plus systolic blood pressure 1.21 (1.15, 1.27) 56 0 (0, 51) 1.21 (1.15, 1.27) 54 0 (0, 54) 
plus smoking‡ 1.19 (1.14, 1.25) 48 0 (0, 51) 1.20 (1.14, 1.26) 47 0 (0, 54) 
plus history of diabetes 1.17 (1.11, 1.23) 37 0 (0, 51) 1.17 (1.11, 1.23) 36 0 (0, 54) 
plus BMI 1.17 (1.11, 1.23) 35 0 (0, 51) 1.17 (1.11, 1.24) 34 0 (0, 54) 
plus loge triglycerides 1.16 (1.10, 1.23) 31 0 (0, 51) 1.16 (1.10, 1.23) 29 0 (0, 54) 
plus total cholesterol 1.17 (1.10, 1.23) 32 0 (0, 51) 1.16 (1.10, 1.23) 30 0 (0, 54) 
plus non-HDL cholesterol§ - - - 1.17 (1.10, 1.23) 30 0 (0, 54) 
plus HDL cholesterol§ - - - 1.16 (1.10, 1.23) 29 0 (0, 54) 
plus alcohol§ - - - 1.16 (1.10, 1.23) 30 0 (0, 54) 
       
All vascular deaths 27 studies, 95583 participants, 1810 events 23 studies, 80905 participants, 1544 events 
Adjusted for age, sex, and study 1.41 (1.32, 1.51) 96 42 (9, 64) 1.39 (1.30, 1.49) 83 37 (0, 62) 
plus systolic blood pressure 1.39 (1.30, 1.49) 89 40 (4, 62) 1.37 (1.27, 1.47) 75 35 (0, 61) 
plus smoking‡ 1.35 (1.27, 1.44) 84 32 (0, 57) 1.33 (1.24, 1.43) 66 30 (0, 58) 
plus history of diabetes 1.34 (1.25, 1.43) 69 37 (0, 61) 1.32 (1.22, 1.41) 54 37 (0, 62) 
plus BMI 1.34 (1.26, 1.44) 79 30 (0, 56) 1.32 (1.23, 1.42) 60 32 (0, 59) 
plus loge triglycerides 1.35 (1.26, 1.44) 75 33 (0, 58) 1.33 (1.23, 1.43) 56 35 (0, 61) 
plus total cholesterol 1.34 (1.26, 1.44) 73 33 (0, 58) 1.32 (1.23, 1.43) 54 36 (0, 61) 
plus non-HDL cholesterol§ - - - 1.33 (1.23, 1.43) 54 37 (0, 62) 
plus HDL cholesterol§ - - - 1.32 (1.23, 1.43) 54 35 (0, 61) 
plus alcohol§ - - - 1.32 (1.23, 1.43) 54 36 (0, 61) 
       
8on-vascular deaths 30 studies, 99863 participants, 5109 events 26 studies, 88399 participants, 4599 events 
Adjusted for age, sex, and study 1.29 (1.22, 1.35) 97 57 (36, 72) 1.29 (1.22, 1.36) 85 60 (38, 74) 
plus systolic blood pressure 1.29 (1.22, 1.35) 98 57 (35, 71) 1.29 (1.22, 1.36) 84 60 (38, 74) 
plus smoking‡ 1.25 (1.19, 1.31) 91 48 (21, 66) 1.25 (1.19, 1.32) 78 52 (24, 69) 
plus history of diabetes 1.24 (1.19, 1.30) 81 51 (25, 68) 1.25 (1.18, 1.31) 69 54 (28, 71) 
plus BMI 1.27 (1.21, 1.34) 87 55 (32, 70) 1.28 (1.21, 1.35) 79 57 (33, 72) 
plus loge triglycerides 1.27 (1.21, 1.34) 92 52 (27, 68) 1.28 (1.21, 1.35) 83 53 (27, 70) 
plus total cholesterol 1.26 (1.20, 1.32) 90 50 (23, 67) 1.27 (1.20, 1.33) 79 52 (25, 69) 
plus non-HDL cholesterol§ - - - 1.27 (1.21, 1.34) 81 52 (25, 70) 
plus HDL cholesterol§ - - - 1.27 (1.21, 1.33) 86 48 (18, 67) 
plus alcohol§ - - - 1.27 (1.20, 1.33) 87 47 (17, 67) 
† Risk ratios are presented per 1.11 higher loge CRP (i.e. 1-SD of observed levels at baseline), corresponding to a 3-fold higher CRP 
levels, progressively adjusted as shown and stratified where appropriate, by sex and trial arm. 
¶ Analyses were restricted to participants with complete information on sex, trial arm, and all confounding variables. Studies with 
fewer than 10 cases were excluded from the analysis of each outcome.  
§ Non-HDL cholesterol has been substituted for total cholesterol in these adjusted models 
I2 is a measure of consistency across studies: the percentage of variance in estimated log RRs that is attributable to between study 
variation as opposed to sampling variation. Values of I2 close to 0 correspond to lack of heterogeneity. 
‡Subsidiary analyses were done in the 37,802 participants who had complete data on all the risk factors in this table plus information 
on pack-years of smoking. In this subset, the RR for CHD, adjusted for the factors listed in the left-hand column above, was 1.14 
(1.08-1.20) and it was almost exactly the same when adjustment also included information on pack-years of smoking. The pattern of 
findings was similar in such subsidiary analyses of other disease endpoints.  
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eTable 9. Risk ratios for major vascular and nonvascular outcomes per 3-fold higher usual CRP levels with 
progressive adjustment for usual levels of potential confounders, pooled by fixed effects meta-analysis. 
 Basic adjustment
¶ Further adjustment¶ 
 RR (95% CI) usual 






I2 (95% CI) RR (95% CI) usual 






I2 (95% CI) 
Coronary heart disease 37 studies, 109742 participants, 8056 events 31 studies, 91990 participants, 5373 events 
Adjusted for age, sex, and study 1.61 (1.54, 1.68) 483 44 (17, 62) 1.61 (1.53, 1.69) 353 51 (26, 68) 
plus systolic blood pressure 1.54 (1.47, 1.61) 377 37 (7, 58) 1.54 (1.46, 1.62) 273 42 (12, 62) 
plus smoking 1.47 (1.40, 1.53) 276 26 (0, 51) 1.47 (1.39, 1.55) 203 30 (0, 55) 
plus history of diabetes 1.42 (1.36, 1.49) 224 38 (7, 58) 1.41 (1.34, 1.49) 156 42 (10, 62) 
plus BMI 1.43 (1.36, 1.50) 197 22 (0, 48) 1.43 (1.35, 1.52) 143 31 (0, 56) 
plus loge triglycerides 1.38 (1.32, 1.46) 159 26 (0, 51) 1.39 (1.31, 1.47) 117 35 (0, 58) 
plus total cholesterol 1.39 (1.32, 1.47) 163 24 (0, 50) 1.40 (1.32, 1.48) 121 33 (0, 57) 
plus non-HDL cholesterol§ - - - 1.39 (1.31, 1.47) 115 26 (0, 53) 
plus HDL cholesterol§ - - - 1.37 (1.29, 1.46) 108 25 (0, 52) 
plus alcohol§ - - - 1.36 (1.29, 1.45) 103 26 (0, 53) 
       
Ischaemic stroke 17 studies, 65825 participants, 2006 events 15 studies, 60763 participants, 1931 events 
Adjusted for age, sex, and study 1.43 (1.32, 1.55) 80 0 (0, 51) 1.43 (1.32, 1.55) 76 7 (0, 57) 
plus systolic blood pressure 1.34 (1.23, 1.45) 50 0 (0, 51) 1.33 (1.23, 1.45) 46 0 (0, 54) 
plus smoking 1.31 (1.20, 1.42) 40 0 (0, 51) 1.31 (1.20, 1.42) 38 0 (0, 54) 
plus history of diabetes 1.25 (1.14, 1.35) 26 0 (0, 51) 1.24 (1.14, 1.36) 25 0 (0, 54) 
plus BMI 1.29 (1.18, 1.41) 29 0 (0, 51) 1.29 (1.18, 1.42) 28 0 (0, 54) 
plus loge triglycerides 1.27 (1.16, 1.40) 26 0 (0, 51) 1.27 (1.15, 1.40) 24 0 (0, 54) 
plus total cholesterol 1.28 (1.17, 1.41) 27 0 (0, 51) 1.28 (1.16, 1.40) 25 0 (0, 54) 
plus non-HDL cholesterol§ - - - 1.28 (1.16, 1.40) 25 0 (0, 54) 
plus HDL cholesterol§ - - - 1.27 (1.16, 1.40) 25 0 (0, 54) 
plus alcohol§ - - - 1.27 (1.15, 1.40) 24 0 (0, 54) 
       
All vascular deaths 27 studies, 95583 participants, 1810 events 23 studies, 80905 participants, 1544 events 
Adjusted for age, sex, and study 1.71 (1.58, 1.85) 175 41 (6, 63) 1.66 (1.53, 1.80) 140 33 (0, 60) 
plus systolic blood pressure 1.65 (1.52, 1.79) 145 36 (0, 60) 1.60 (1.47, 1.74) 114 30 (0, 58) 
plus smoking 1.59 (1.46, 1.73) 118 22 (0, 52) 1.55 (1.42, 1.69) 95 28 (0, 57) 
plus history of diabetes 1.52 (1.40, 1.66) 94 23 (0, 52) 1.47 (1.34, 1.61) 71 22 (0, 53) 
plus BMI 1.61 (1.47, 1.76) 105 24 (0, 53) 1.57 (1.42, 1.73) 85 38 (0, 63) 
plus loge triglycerides 1.59 (1.45, 1.74) 97 18 (0, 49) 1.53 (1.39, 1.69) 74 21 (0, 53) 
plus total cholesterol 1.60 (1.46, 1.75) 102 30 (0, 56) 1.57 (1.43, 1.73) 85 58 (34, 74) 
plus non-HDL cholesterol§ - - - 1.53 (1.39, 1.69) 73 23 (0, 54) 
plus HDL cholesterol§ - - - 1.56 (1.42, 1.72) 80 60 (37, 75) 
plus alcohol§ - - - 1.56 (1.42, 1.72) 80 64 (44, 77) 
       
8on-vascular deaths 30 studies, 99863 participants, 5109 events 26 studies, 88399 participants, 4599 events 
Adjusted for age, sex, and study 1.46 (1.39, 1.53) 247 56 (34, 71) 1.45 (1.38, 1.52) 219 58 (34, 73) 
plus systolic blood pressure 1.47 (1.40, 1.54) 247 54 (30, 70) 1.46 (1.39, 1.54) 221 56 (32, 72) 
plus smoking 1.41 (1.34, 1.48) 187 45 (15, 64) 1.40 (1.33, 1.48) 166 47 (16, 66) 
plus history of diabetes 1.38 (1.31, 1.45) 160 50 (24, 67) 1.37 (1.30, 1.44) 142 53 (26, 70) 
plus BMI 1.48 (1.40, 1.56) 206 54 (31, 70) 1.47 (1.39, 1.55) 183 55 (30, 71) 
plus loge triglycerides 1.49 (1.41, 1.57) 209 52 (27, 68) 1.48 (1.40, 1.56) 186 52 (25, 70) 
plus total cholesterol 1.47 (1.39, 1.55) 199 50 (24, 67) 1.46 (1.38, 1.54) 177 51 (23, 69) 
plus non-HDL cholesterol§ - - - 1.47 (1.39, 1.55) 181 50 (22, 68) 
plus HDL cholesterol§ - - - 1.47 (1.39, 1.55) 181 46 (15, 66) 
plus alcohol§ - - - 1.46 (1.38, 1.54) 175 45 (12, 65) 
† Risk ratios are presented per 1.11 higher loge CRP (i.e. 1-SD of observed levels at baseline), corresponding to a 3-fold 
higher CRP levels, progressively adjusted as shown and stratified where appropriate, by sex and trial arm. 
¶ Analyses were restricted to participants with complete information on sex, trial arm, and all confounding variables. 
Studies with fewer than 10 cases were excluded from the analysis of each outcome.  
§ Non-HDL cholesterol has been substituted for total cholesterol in these adjusted models 
I2 is a measure of consistency across studies: the percentage of variance in estimated log RRs that is attributable to 
between study variation as opposed to sampling variation. Values of I2 close to 0 correspond to lack of heterogeneity. 
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eTable 10. Risk ratios for vascular and nonvascular mortality without censoring for non-fatal events per 3-fold 
higher usual CRP levels with progres9sive adjustment for usual levels of potential confounders. 
 
 Basic adjustment
¶ Further adjustment¶ 
 RR (95% CI) usual 






I2 (95% CI) RR (95% CI) usual 






I2 (95% CI) 
All vascular deaths 28 studies, 96025 participants, 3196 events 23 studies, 81311 participants, 2795 events 
Adjusted for age, sex, and study 1.79 (1.64, 1.95) 173 39 (4, 61) 1.76 (1.60, 1.93) 134 43 (7, 65) 
plus systolic blood pressure 1.70 (1.56, 1.85) 153 33 (0, 58) 1.67 (1.52, 1.83) 120 36 (0, 61) 
plus smoking 1.62 (1.50, 1.74) 165 14 (0, 46) 1.60 (1.47, 1.74) 117 24 (0, 54) 
plus history of diabetes 1.56 (1.44, 1.69) 114 24 (0, 52) 1.52 (1.39, 1.66) 87 26 (0, 55) 
plus BMI 1.65 (1.51, 1.80) 132 21 (0, 50) 1.62 (1.47, 1.78) 96 27 (0, 56) 
plus loge triglycerides 1.59 (1.48, 1.71) 151 6 (0, 37) 1.57 (1.44, 1.71) 104 15 (0, 48) 
plus total cholesterol 1.63 (1.50, 1.78) 124 21 (0, 50) 1.61 (1.45, 1.78) 86 31 (0, 58) 
plus non-HDL cholesterol§ - - - 1.57 (1.44, 1.72) 102 16 (0, 49) 
plus HDL cholesterol§ - - - 1.57 (1.44, 1.71) 105 14 (0, 48) 
plus alcohol§ - - - 1.57 (1.44, 1.71) 102 15 (0, 48) 
       
8on-vascular deaths 31 studies, 100302 participants, 6255 events 26 studies, 88802 participants, 5518 events 
Adjusted for age, sex, and study 1.53 (1.41, 1.65) 111 60 (40, 73) 1.55 (1.42, 1.69) 100 62 (43, 75) 
plus systolic blood pressure 1.54 (1.42, 1.66) 110 59 (40, 73) 1.56 (1.43, 1.70) 99 62 (42, 75) 
plus smoking 1.45 (1.34, 1.56) 94 51 (25, 67) 1.46 (1.35, 1.59) 83 53 (27, 70) 
plus history of diabetes 1.42 (1.32, 1.54) 77 54 (31, 69) 1.44 (1.32, 1.57) 68 57 (34, 72) 
plus BMI 1.53 (1.40, 1.67) 88 58 (38, 72) 1.56 (1.42, 1.72) 83 59 (37, 73) 
plus loge triglycerides 1.54 (1.41, 1.68) 93 57 (36, 71) 1.56 (1.42, 1.72) 89 57 (33, 72) 
plus total cholesterol 1.52 (1.40, 1.66) 91 56 (34, 70) 1.55 (1.41, 1.69) 86 56 (31, 71) 
plus non-HDL cholesterol§ - - - 1.55 (1.42, 1.70) 89 55 (30, 71) 
plus HDL cholesterol§ - - - 1.55 (1.41, 1.69) 93 52 (25, 69) 
plus alcohol§ - - - 1.53 (1.40, 1.67) 90 51 (22, 69) 
 
† Risk ratios are presented per 1.11 higher loge CRP (i.e. 1-SD of observed levels at baseline), corresponding to a 3-fold 
higher CRP levels, progressively adjusted as shown and stratified where appropriate, by sex and trial arm. 
¶ Analyses were restricted to participants with complete information on sex, trial arm, and all confounding variables. 
Studies with fewer than 10 cases were excluded from the analysis of each outcome.  
§ Non-HDL cholesterol has been substituted for total cholesterol in these adjusted models 
I2 is a measure of consistency across studies: the percentage of variance in estimated log RRs that is attributable to 






eFigure 1. Study flow diagram 
 
135 potentially relevant articles retrieved 
1 study involving approximately 389 CHD cases 
(~4% of the potentially available cases for 
analyses) was not able to provide data
2467 excluded based on titles and/or abstracts 
due to not fulfilling the inclusion criteria (no 
relevant CRP data, cross-sectional or 
retrospective case-control design, study sample 
entirely diseased population, reviews, animal 
studies, etc.)
94 did not fulfil the inclusion criteria or 
were duplicate publications
2602 citations identified through electronic search and 
search of the reference list of relevant articles published 
before 30/06/2008
14 additional studies that had not previously published their CRP 
findings were identified through discussion with collaborators 
which, along with the 41 studies identified in literature, gave a  
total of 55 relevant studies
54 studies provided data for the current analyses 
involving a total of 160,309 participants
 
 
Studies were identified through electronic search of databases, scanning of the reference list of relevant articles 
(including previously published reviews) and discussion with investigators. Electronic searches, not limited to the 
English language, were performed in MEDLINE and EMBASE for studies published between January 1970 and June 
2008 using terms related to CRP (e.g. “C-reactive protein”, “CRP”) and cardiovascular disease outcomes (e.g. 
“cardiovascular disease”, “coronary heart disease”, “myocardial infarction”, “stroke”). Studies were considered for 
inclusion if they had baseline information on age, sex, CRP and conventional vascular risk factors; if they did not select 
participants on the basis of having previous cardiovascular disease; used well-described assay methods; recorded cause-
specific mortality and/or vascular morbidity using accepted criteria; and had accrued >1-year of follow-up. The reported 















































































































































0 5 10 15 20
Time since baseline (yrs)
Overall RDR (95% CI) adjusted for age and sex = 0.58 (0.52, 0.63)
14 cohorts, 22124 participants, 24222 repeats
 
 
The size of the markers are inversely proportional to the variance of the regression dilution ratio. CI indicates 
confidence interval. 
 
Comparisons were done to assess the comparability of baseline characteristics of the 22,124 participants who provided 
repeat CRP measurements with others in the same studies. Compared with individuals who did not provide repeat CRP 
measurements, participants who did so tended to be younger (p=0.002), less likely to be smokers(p=0.02)  or to be 
diagnosed with diabetes (p=0.002), and had lower systolic blood pressure (p=0.009). These two groups did not, 
however, differ  significantly in relation to sex composition, CRP concentration, body mass index, and concentration of 







eFigure 3. Risk ratios for major vascular and nonvascular outcomes by quantiles of CRP levels, with different 
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Coronary heart disease
25 studies 2492 cases
Ischaemic stroke
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Coronary heart disease
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Ischaemic stroke
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All vascular deaths
11 studies 581 cases
All nonvascular deaths
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Adjusted study-specific log risk ratios were combined by multivariate random effects meta-analysis. The adjustments 
included age, sex, and study only in column (a); age, sex, study, systolic blood pressure, smoking, history of diabetes, 
BMI, loge triglycerides, non-HDL cholesterol, HDL cholesterol, and alcohol consumption, in column (b); and the 
preceding plus fibrinogen in column (c). Studies with fewer than 10 cases of any outcome were excluded from the 
analysis of that outcome. CI indicates confidence interval, calculated using floating absolute risk technique. The sizes of 




eFigure 4. Age- and sex- adjusted only risk ratios for vascular and non-vascular mortality per 3-fold higher 
usual CRP levels after (a) excluding current smokers and (b) excluding data from first 5 years of follow up. 
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Risk ratios are adjusted only for age, and stratified where appropriate, by sex and trial arm. Studies with fewer than 10 
cases of the composite all vascular and all non vascular deaths outcomes or 5 cases of the specific nonvascular 
outcomes were excluded from the analysis of that outcome. The risk ratios are presented per 1.11 higher loge CRP (i.e. 
1-SD of observed levels at baseline), corresponding to a 3-fold higher CRP levels. Respiratory diseases included 
Chronic Obstructive Pulmonary Disease (COPD) and related conditions including ICD10 codes J40 – J47 (Bronchitis, 
Emphysema, Asthma, Other COPD, etc). CI indicates confidence interval. The sizes of data markers are proportional to 





eFigure 5. Direct comparison of risk ratios for coronary heart disease per 1-SD higher loge CRP with those of 
systolic blood pressure and lipids mutually adjusted for each other plus other conventional risk factors. 
 
(a) Baseline levels of risk factors adjusted for baseline levels of confounders 
 
Loge CRP (loge mg/l)



















Risk ratio (95% CI)
1.0 1.2 1.4 1.8
Risk ratio (95% CI) per 1 SD higher baseline values  
 
(b) Usual levels of risk factors adjusted for usual levels of confounders 
 
Loge CRP (loge mg/l)



















Risk ratio (95% CI)
1.0 1.2 1.4 1.8
Risk ratio (95% CI) per 1 SD higher usual values  
 
* The direct comparisons used data from 91990 participants (5373 CHD events) from 31 studies with concomitant 
information on these risk factors plus age, sex, smoking status, history of diabetes, BMI, loge triglycerides, and alcohol 
consumption that were adjusted for. The model for non-HDL cholesterol substituted HDL cholesterol in place of total 
cholesterol in the adjustment.  
† The regression dilution ratio (RDR) is an indicator of the long-term within person consistency of the values for each 
risk marker. RDR values range between 0 and 1, with values closer to 1 indicating high within person consistency of 
measured values. The RDRs were adjusted for baseline values of the risk factors included in the CHD risk model. 
‡ Baseline SD refers to the standard deviation of observed values at baseline. CI indicates confidence interval. The sizes 
































































































































1.00.8 1.4 2.0 2.8
Risk ratio (95% CI) per 3-fold higher usual CRP  
 
Study-specific risk ratios were adjusted for age, sex, systolic BP, smoking, history of diabetes, BMI, loge triglycerides, 
non-HDL cholesterol, HDL cholesterol, and alcohol consumption, stratified where appropriate, by sex and trial arm. 
Studies with fewer than 10 cases were excluded from the analysis. CI indicates confidence interval. The sizes of data 


















































































1.00.8 1.4 2.0 2.8
Risk ratio (95%CI) per 1 SD higher usual CRP  
 
Study-specific risk ratios were adjusted for age, sex, systolic BP, smoking, history of diabetes, BMI, loge triglycerides, 
non-HDL cholesterol, HDL cholesterol, and alcohol consumption, stratified where appropriate, by sex and trial arm. 
Studies with fewer than 10 cases were excluded from the analysis. CI indicates confidence interval. The sizes of data 




eFigure 8. Study-specific risk ratios for CHD per 3-fold higher usual CRP levels adjusted for all the factors in 
the final model in Table 2. 
 
(a) Adjusted for age, sex, systolic blood pressure, smoking, history of diabetes, BMI, loge triglycerides, total 
cholesterol, and stratified where appropriate, by sex and trial arm. 
































































































































































1.00.2 0.5 2.0 4.0 8.0
Risk ratio (95% CI) per 3-fold higher usual CRP
 
 (b) Adjusted for age, sex, systolic blood pressure, smoking, history of diabetes, BMI, loge triglycerides, non-HDL 
cholesterol, HDL cholesterol, alcohol consumption, and stratified where appropriate, by sex and trial arm. 
 








































































































































1.00.2 0.5 2.0 4.0 8.0
Risk ratio (95% CI) per 3-fold higher usual CRP
 
CI indicates confidence interval. The sizes of data markers are proportional to the inverse of the variance of the risk 
ratios. Test for heterogeneity were: I2 (95% CI) = 24% (0%, 50%), p=0.096 in (a) and 26% (0%, 53%), p=0.095 n (b), 
but the small residual heterogeneity was not significantly explained by study size as measured by the number of CHD 




eFigure 9. Risk ratios for vascular and nonvascular mortality without censoring for non-fatal outcomes by 
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Adjusted study-specific log risk ratios were combined by multivariate random effects meta-analysis. The adjustments 
included age, sex, and study only in column (a); age, sex, study, systolic blood pressure, smoking, history of diabetes, 
BMI, loge triglycerides, non-HDL cholesterol, HDL cholesterol, and alcohol consumption, in column (b); and the 
preceding plus fibrinogen in column (c). Studies with fewer than 10 cases of any outcome were excluded from the 
analysis of that outcome. CI indicates confidence interval, calculated using floating absolute risk technique. The sizes of 






eFigure 10. Meta-regression plots assessing potential bias from small study effects in the meta-analysis of 
association of CRP levels and CHD risk. 
 
(a) Adjusted for age, sex, systolic blood pressure, smoking, history of diabetes, BMI, loge triglycerides, total 



























































































































































































































 (b) Adjusted for age, sex, systolic blood pressure, smoking, history of diabetes, BMI, loge triglycerides, non-HDL 


































































































































































































The horizontal solid line shows the overall random effect pooled estimate with 95% CI indicated by the dashed lines. 
The thick solid line corresponds to the meta-regression of log RR on number of CHD cases. The sizes of the markers 
are inversely proportional to the variance of the log RR in each study. There was no evidence of bias from small-studies 
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